Bruker Corporation Appoints William J. Knight to Chief Operating Officer and Brian P. Monahan to Chief Financial Officer

BILLERICA, Mass.--(Business Wire)--
Bruker Corporation (NASDAQ: BRKR) today announced that its Board of Directors
has appointed Bill Knight to Chief Operating Officer (COO) and Brian Monahan to
Chief Financial Officer (CFO), with an effective date of February 1st, 2010.
Presently, Bill Knight is serving as CFO, and Brian Monahan is serving as Chief
Accounting Officer of Bruker Corporation.

Frank Laukien, Bruker`s President and CEO, stated: "Bruker has a 49 year proud
history of technology leadership and customer-focused product innovation. Going
forward, we believe that the combination of continued innovation and an
increased focus on operational excellence will drive margin expansion, balance
sheet metrics and cash flow for increasing shareholder value. In order to drive
our operational excellence initiative, we have created the new position of Chief
Operating Officer at Bruker Corporation."

He continued: "Today, we are very pleased to announce the promotion of two
extremely capable individuals to expanded responsibilities. Over the past five
years, Bill Knight has demonstrated strong financial and operational leadership
at Bruker, and in his newly-created COO role Bill will lead and fully focus on
our operation excellence initiative. Brian Monahan has been a key leader and
contributor in our finance organization over the past five years, and we believe
he is an excellent choice to succeed Bill as our CFO."

Biographies

Mr. Knight joined Bruker Corporation as CFO and Treasurer in October 2004. At
Bruker, Mr. Knight is also the President of the Bruker Detection business in the
United States. Before joining the Company, Mr. Knight served as an
operations-focused CFO in several public companies, and was a founder of ATI
Technologies, an analytical instruments company, where he had both financial and
operational responsibilities. Mr. Knight served as CFO of Anika Therapeutics,
Inc., from 2002 to 2004. He served as CFO of Zycos, Inc., a developer of
DNA-based therapeutic products, from 2000 to 2002, and as CFO of NMT Medical,
Inc., a provider of cardiovascular and neurological medical devices, from 1998
to 2000. Mr. Knight is a Certified Public Accountant and holds a B.B.A. in
Accounting from the University of Wisconsin.

Mr. Monahan joined Bruker Corporation as the Corporate Controller in April 2004
and was appointed Chief Accounting Officer and Vice President of Finance in
March 2009. In addition to his corporate responsibilities, Mr. Monahan has
served in both financial and operational roles in the Bruker Daltonics division,
where he has been an Executive Vice President of Bruker Daltonics since November
2006 and General Manager of the Americas since July 2008. From January 2005 to
November 2006, Mr. Monahan was Vice President of Finance for Bruker Daltonics,
and from July 2004 to January 2005 he was Assistant Vice President of Finance
for Bruker Daltonics. Before joining the Company, from 2002 through 2004, Mr.
Monahan served as the Manager of Accounting and Financial Reporting at Fisher
Scientific International, Inc., and as an audit manager for
PricewaterhouseCoopers LLP from 1999 through 2002. Mr. Monahan is a Certified
Public Accountant and holds a B.S. in Accounting from the University of
Massachusetts.

ABOUT BRUKER CORPORATION

Bruker Corporation is a leading provider of high-performance scientific
instruments and solutions for molecular and materials research, as well as for
industrial and applied analysis. For more information about Bruker Corporation,
please visit www.bruker.com.

CAUTIONARY STATEMENT

Any statements contained in this press release that do not describe historical
facts may constitute forward-looking statements as that term is defined in the
Private Securities Litigation Reform Act of 1995. Any forward-looking statements
contained herein are based on current expectations, but are subject to risks and
uncertainties, that could cause actual future results to differ materially from
those projected including, but are not limited to, risks and uncertainties
relating to adverse changes in conditions in the global economy and volatility
in the capital markets, the integration of businesses we have acquired or may
acquire in the future, changing technologies, product development and market
acceptance of our products, the cost and pricing of our products, manufacturing,
competition, dependence on collaborative partners and key suppliers, capital
spending and government funding policies, changes in governmental regulations,
realization of anticipated benefits from economic stimulus programs,
intellectual property rights, litigation, and exposure to foreign currency
fluctuations and other risk factors discussed from time to time in our filings
with the Securities and Exchange Commission. These and other factors are
identified and described in more detail in our filings with the SEC, including,
without limitation, our recent Proxy Statements on Schedule 14A, our annual
report on Form 10-K for the year ended December 31, 2008, our most recent
quarterly reports on Form 10-Q and our current reports on Form 8-K. We expressly
disclaim any intent or obligation to update these forward-looking statements
other than as required by law.

Bruker Corporation
Stacey Desrochers, +1-978-663-3660, ext. 1115
Director of Investor Relations
stacey.desrochers@bruker.com

Copyright Business Wire 2009